Well, tell us, is there any profitable growth company that would be better than this one?
This year will also be profitable, and profit is conservatively estimated to be +20-40% compared to last year. In my books, there is nothing better than this.
4 Likes
Not even close. They’re on completely different levels. They just got a nearly 600 million order. Grew by about 60% last year.
Well, I forgot to mention that I’m in Finland. I only invest in the US and Finland, not Stockholm. So, is there an equivalent for this in Finland?
1 Like
Sinaptica CEO as a guest
15 Likes
Sinaptica is firing up its first machine this July in Florida, so the research continues, and we’re hoping for some strong results.
18 Likes
Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications
Press Release, Helsinki, 10 July 2026 at 9 AM (EEST)
Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications
Nexstim Plc (“Nexstim” or the “Company”) has received approval from Health Canada for a licence amendment expanding the approved indications of the NBS 6 to include diagnostic applications and the treatment of chronic neuropathic pain in Canada. The NBS 6 was previously approved by Health Canada for the treatment of Major Depressive Disorder (MDD) in 2024.
The expanded approval allows Nexstim to market and commercially distribute the NBS 6 in Canada for pre-procedural mapping of the speech and motor cortices of the brain, the treatment of MDD, and the treatment of chronic neuropathic pain.
Nexstim has maintained a presence in the Canadian market for several years . In March 2019, Health Canada granted medical device licences for the NBS System 5 and NexSpeech® for pre-procedural motor and speech mapping. Later that year, in December 2019, Health Canada approved the NBT® System for the treatment of Major Depressive Disorder.
Nexstim’s latest product generation, the NBS 6, was released for therapy use in Europe and the United States in 2023 and for diagnostic use in these markets in 2025. The NBS 6 is a modular platform built on Nexstim’s proprietary SmartFocus® nTMS technology. The system combines diagnostic and therapeutic capabilities and can be configured to meet the needs of individual clinical and research users.
Mikko Karvinen, CEO of Nexstim, comments:
“We are pleased to receive this expanded approval from Health Canada, which broadens the commercial opportunities for NBS 6 in Canada. With approvals now covering diagnostics, MDD treatment and chronic neuropathic pain, we can offer Canadian customers access to a comprehensive navigated TMS platform that supports both diagnostic and therapeutic applications. Canada remains an important market for Nexstim, and we look forward to continuing our cooperation with our local partners and customers.”
35 Likes
Positive news won’t drive the stock price up until there’s concrete information on the growth percentage at which this story is advancing. Nothing to do but wait for the H1 report on August 14th, unless bigger news comes out before then. Still, the story is progressing consistently. Staying on board with peace of mind 
.
11 Likes
Köpi reduced its holdings by almost 19,000 shares last month; without any major news, the share price will likely remain around ten [currency units] if the K2 sales continue.
4 Likes
Perhaps Köpi hasn’t listened to that podcast linked by @Kyhnykeisari yet; everyone should watch the section from 30:00-32:00 in particular. A direct link with a timestamp to that part, with a small pre-disclaimer: https://www.youtube.com/watch?v=2EFNW2SFkYw&t=1766s
Pay attention to the interviewer’s reaction at 31:18, when Ken says:
The pivotal trial will have a six-month endpoint, which is relatively fast. We’re not going to keep patients on placebo for 18 months. The the endpoint, by the way, is the IDARS endpoint that’s been negotiated with FDA. IDARIS is a global well-established measure of dementia where we actually showed 102% slowing, um, in air quotes 102% slowing, means we stopped the disease based on that endpoint at 24 weeks.
That part about “The pivotal trial will have a six-month endpoint” also sounds really fast.
17 Likes
I’m in this case until the very end, so to speak. There are no dark clouds on the horizon. I don’t think it matters why some investment mogul is reducing their position, because there can be many personal reasons for that. Back in the day, they sold their Revenio stake at €28–29, which some people laughed at later on. I don’t think anyone is laughing at that move right now. The money probably went into Endomines, a summer house, and other companies.
15 Likes
Same here, this is growing nicely though, and there’s no pressure on the cash position either. The rest is just a matter of waiting. But as long as the setup seems to be playing out this well, there’s no reason to sell. And at this point, we should start seeing orders from new regions as well, plus the Brainlab orders should really start to show by the end of the year. The share price is whatever it is right now, I’m not worried about that.
14 Likes
Certainly, some of the deals for the end of the year will end up slipping into 2027 anyway, and surely some will get spooked by that too 
For me personally, things like that don’t matter regarding the end of the year, but I have noticed that many people really don’t think beyond fifteen minutes.
8 Likes